Prostate Cancer

Mohler, James L.; Bahnson, Robert R.; Boston, Barry; Busby, J. Erik; D’Amico, Anthony V.; Eastham, James A.; Enke, Charles Arthur; George, Daniel; Horwitz, Eric M.; Huben, Robert P.; Kantoff, Philip W.; Kawachi, Mark H.; Kuettel, Michael; Lange, Paul H.; MacVicar, Gary R.; Plimack, Elizabeth R.; Pow‐Sang, Julio M.; Roach, Mack; Rohren, Eric M.; Roth, Bruce J.; Shrieve, Dennis C.; Smith, Matthew R.; Srinivas, Sandy; Twardowski, Przemyslaw; Walsh, Patrick C.

doi:10.6004/jnccn.2010.0012

Cited by 650 publications

(182 citation statements)

References 173 publications

Supporting

Mentioning

179

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, its use in this setting is still a matter of debate. Due to the lack of robust clinical evidence showing benefit (or equivalence) in comparison with standard treatments, HIFU is still considered ‘experimental' by the European Association of Urology [2] and the National Comprehensive Cancer Network guidelines [3], and HIFU devices are unregistered in the United States. Moreover, little is known about salvage therapy for the 15-50% of patients presenting with local relapse after HIFU as primary therapy [4].…”

Section: Introductionmentioning

confidence: 99%

Salvage External Beam Radiotherapy for Recurrent Prostate Adenocarcinoma after High-Intensity Focused Ultrasound as Primary Treatment

et al. 2013

View full text Add to dashboard Cite

Introduction: The main objective was to evaluate feasibility, toxicity and biochemical control rates of salvage external beam radiotherapy (EBRT) in recurrent localized prostate cancer after high-intensity focused ultrasound (HIFU) as primary therapy. Patients and Methods: A total of 24 patients who underwent salvage EBRT after 1 or 2 HIFU sessions and with a minimum post-treatment follow-up of 24 months were retrospectively evaluated. Primary endpoints were toxicity and biochemical disease-free survival (bDFS, defined according to the ASTRO Phoenix definition). Results: Median follow-up was 40.3 months. Gastrointestinal toxicity was low. Acute genitourinary (GU) toxicity grade ≤II rate was 45.8%, with only few patients presenting grade III (8.3%) and grade IV (4.2%) toxicity. Late grade ≥III GU toxicity was registered in 16.7% of patients. The 3-year bDFS rate was 77.8%. Patients achieving a nadir prostate-specific antigen (nPSA) of ≤0.35 ng/ml after EBRT had significantly higher bDFS (3-year bDFS: 87.7 vs. 50%, respectively; p = 0.001). Achieving nPSA ≤0.35 ng/ml was the only factor independently associated to long-term bDFS both on univariate (p = 0.01) and multivariate analysis (HR 7.06, p = 0.039). Conclusions: Salvage EBRT after HIFU failure is feasible and allows to obtain satisfactory biochemical control rates, especially in patients attaining a nPSA ≤0.35 ng/ml after EBRT.

show abstract

Section: Introductionmentioning

confidence: 99%

Salvage External Beam Radiotherapy for Recurrent Prostate Adenocarcinoma after High-Intensity Focused Ultrasound as Primary Treatment

et al. 2013

View full text Add to dashboard Cite

show abstract

“…These tumours based on the National Comprehensive Cancer Network classification system (Mohler et al ., 2010) are characterised by their clinical behaviour as indolent, slow‐growing tumours. However, PCa can also be aggressive and fast‐growing with lethal progression (Penney et al ., 2011).…”

Section: Introductionmentioning

confidence: 99%

Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer

Murphy

Boyce

et al. 2018

Molecular Oncology

View full text Add to dashboard Cite

Classifying indolent prostate cancer represents a significant clinical challenge. We investigated whether integrating data from different omic platforms could identify a biomarker panel with improved performance compared to individual platforms alone. DNA methylation, transcripts, protein and glycosylation biomarkers were assessed in a single cohort of patients treated by radical prostatectomy. Novel multiblock statistical data integration approaches were used to deal with missing data and modelled via stepwise multinomial logistic regression, or LASSO. After applying leave‐one‐out cross‐validation to each model, the probabilistic predictions of disease type for each individual panel were aggregated to improve prediction accuracy using all available information for a given patient. Through assessment of three performance parameters of area under the curve (AUC) values, calibration and decision curve analysis, the study identified an integrated biomarker panel which predicts disease type with a high level of accuracy, with Multi AUC value of 0.91 (0.89, 0.94) and Ordinal C‐Index (ORC) value of 0.94 (0.91, 0.96), which was significantly improved compared to the values for the clinical panel alone of 0.67 (0.62, 0.72) Multi AUC and 0.72 (0.67, 0.78) ORC. Biomarker integration across different omic platforms significantly improves prediction accuracy. We provide a novel multiplatform approach for the analysis, determination and performance assessment of novel panels which can be applied to other diseases. With further refinement and validation, this panel could form a tool to help inform appropriate treatment strategies impacting on patient outcome in early stage prostate cancer.

show abstract

“…Current AS protocols accept up to one positive biopsy core out of three cores taken as an inclusion criterion [5]. Patients with up to two positive biopsy cores are accepted in the vast majority of AS cohorts, regardless of the distance between the two positive cores [4,6]. Indeed, this distance is very difficult to ascertain in clinical practice and is therefore generally not useful as an additional proxy parameter for tumor volume.…”

Section: Introductionmentioning

confidence: 99%

Bilaterally Positive Biopsy Cores Are Associated with Non-Organ-Confined Disease in Prostate Cancer Patients Eligible for Active Surveillance

Umbehr

Largo²,

Gfeller³

et al. 2014

Urol Int

View full text Add to dashboard Cite

Purpose: To investigate the association between the laterality of diagnostic prostate cancer-positive biopsy cores and definitive tumor stage on final pathology (organ-confined versus non-organ-confined). Patients and Methods: This is a retrospective analysis of 165 men after radical prostatectomy fulfilling our active surveillance criteria at the time of surgery. Nominal variables were compared using Fisher's exact test, continuous variables using Mann-Whitney test. Odds ratios including 95% Wald and probabilities including 95% Wilson confidence intervals are provided. Results: 5 (3%) patients had non-organ-confined disease: 2 out of 144 (1%) patients with unilateral and 3 out of 17 (18%) patients with bilateral cancer-positive biopsy cores (p = 0.009). The estimated odds ratio for non-organ-confined disease was 14.67 (95% confidence interval 1.55-189.23) for patients with bilateral compared to patients with unilateral cancer-positive biopsy cores. The sensitivity, specificity and accuracy of bilaterally positive biopsies as an additional criterion to identify non-organ-confined disease are 60, 91 and 90%, respectively. Conclusion: In our cohort, patients with bilaterally positive biopsy cores were significantly more likely to harbor a non-organ-confined tumor than patients with unilaterally positive cores. Due to their high specificity, bilaterally positive biopsies may represent a reasonable exclusion criterion for active surveillance if our results are corroborated in further studies.

show abstract

Prostate Cancer

Cited by 650 publications

References 173 publications

Salvage External Beam Radiotherapy for Recurrent Prostate Adenocarcinoma after High-Intensity Focused Ultrasound as Primary Treatment

Salvage External Beam Radiotherapy for Recurrent Prostate Adenocarcinoma after High-Intensity Focused Ultrasound as Primary Treatment

Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer

Bilaterally Positive Biopsy Cores Are Associated with Non-Organ-Confined Disease in Prostate Cancer Patients Eligible for Active Surveillance

Contact Info

Product

Resources

About